Defeating MYC with drug combinations or dual-targeting drugs
PE Thompson, J Shortt - Trends in Pharmacological Sciences, 2024 - cell.com
Members of the MYC family of proteins are a major target for cancer drug discovery, but the
development of drugs that block MYC-driven cancers has not yet been successful …
development of drugs that block MYC-driven cancers has not yet been successful …
WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)
JA Coker, SR Stauffer - Expert Opinion on Therapeutic Patents, 2025 - Taylor & Francis
Introduction WDR5 is an epigenetic scaffolding protein that has attracted significant interest
as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable …
as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable …
Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia
G Long, X Wang, X Chen, S Ma, L Sun… - Journal of Medicinal …, 2025 - ACS Publications
Targeting the WDR5–MLL1 protein–protein interaction (PPI) is considered to be an effective
approach for the treatment of MLL-rearranged leukemia. However, interfering with WDR5 …
approach for the treatment of MLL-rearranged leukemia. However, interfering with WDR5 …
Precision Targeting of BET Proteins-Navigating Disease Pathways, Inhibitor Insights, and Shaping Therapeutic Frontiers: A Comprehensive Review
RD Amrutkar, MV Amesar, LB Chavan… - Current Drug …, 2024 - benthamdirect.com
The family of proteins known as Bromodomain and Extra-Terminal (BET) proteins has
become a key participant in the control of gene expression, having a significant impact on …
become a key participant in the control of gene expression, having a significant impact on …